Cited by 326Ultrasound and Hyperthermia ApplicationsAlzheimer's disease research and treatmentsBarrier Structure and Function Studies

Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound

Open access
Jordão, Jessica F., Thévenot, Emmanuel, Markham-Coultes, Kelly, Scarcelli, Tiffany, Weng, Ying-Qi, Xhima, Kristiana, O'Reilly, Meaghan, Huang, Yuexi +3 more·2013·Experimental Neurology

Abstract

Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood-brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS can deliver intravenously-administered antibodies to the brain of a mouse model of Alzheimer's disease (AD) and rapidly reduce plaques composed of amyloid-β peptides (Aβ). Here, we investigated two potential effects of transcranial FUS itself that could contribute to a reduction of plaque pathology, namely the delivery of endogenous antibodies to the brain and the activation of glial cells. We demonstrate that transcranial FUS application leads to a significant reduction in plaque burden four days after a single treatment in the TgCRND8 mouse model of AD and that endogenous antibodies are found bound to Aβ plaques. Immunohistochemical and western blot analyses showed an increase in endogenous immunoglobulins within the FUS-targeted cortex. Subsequently, microglia and astrocytes in FUS-treated cortical regions show signs of activation through increases in protein expression and changes in glial size, without changes in glial cell numbers. Enhanced activation of glia correlated with increased internalization of Aβ in microglia and astrocytes. Together these data demonstrate that FUS improved the bioavailability of endogenous antibodies and led to a temporal activation of glial cells, providing evidence towards antibody- and glia-dependent mechanisms of FUS-mediated plaque reduction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2013.05.008

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Jordão JF 2010 Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer’s disease PLoS One 5 e10549 20485502 PMC2868024

Cited by

Sorted by citations

Authors
Jordão, J. F., Thévenot, E., Markham-Coultes, K., Scarcelli, T., Weng, Y.-Q., Xhima, K., O'Reilly, M., Huang, Y., McLaurin, J., Hynynen, K., & Aubert, I.
Affiliations
  • University of Toronto (CA)
  • Sunnybrook Research Institute (CA)
Corresponding author
  • Hynynen, Kullervo
  • Aubert, Isabelle
Venue
Experimental Neurology
Publisher
Elsevier BV
Published
2013-10
Volume
248
Pages
16-29
ISSN
0014-4886 (ISSN-L)
OpenAlex
W2108277337
Cited by
326
References
62
Citations by year
2026: 15 · 2025: 22 · 2024: 21 · 2023: 35 · 2022: 35 · 2021: 37 · 2020: 34 · 2019: 29 · 2018: 29 · 2017: 22 · 2016: 16 · 2015: 18 · 2014: 11 · 2013: 1
FWCI
8.45
Type
journal article
Language
en
Open access
Locations
  • Experimental Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Ontario Mental Health Foundation
  • National Institutes of Health (EB003268)
  • Canadian Institutes of Health Research (FRN 93603, FRN 10246)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
transcranial focused ultrasound, amyloid plaques, Alzheimer's disease, endogenous antibodies, blood-brain barrier permeability, glial activation, microglia, astrocytes, TgCRND8 mice
MeSH terms
Alzheimer Disease, Animals, Blood-Brain Barrier, Brain, Female, Immunoglobulin G, Immunoglobulin M, Male, Mice, Transgenic, Neuroglia, Ultrasonography, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review